BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36843300)

  • 1. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.
    Barba Bernal R; Ferrigno B; Medina Morales E; Castro CM; Goyes D; Trivedi H; Patwardhan VR; Bonder A
    Turk J Gastroenterol; 2023 Feb; 34(2):89-100. PubMed ID: 36843300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Treatment Options for Primary Biliary Cholangitis.
    Wong KA; Bahar R; Liu CH; Bowlus CL
    Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach.
    Mousa HS; Carbone M; Malinverno F; Ronca V; Gershwin ME; Invernizzi P
    Autoimmun Rev; 2016 Sep; 15(9):870-6. PubMed ID: 27393766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying therapies and symptomatic management for primary biliary cholangitis.
    Patel R; Portone G; Lambert JA; Mak S; Alrubaiy L
    Br J Hosp Med (Lond); 2021 Nov; 82(11):1-9. PubMed ID: 34817254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and potential treatments for primary biliary cholangitis.
    Shah RA; Kowdley KV
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies.
    Liu CH; Bowlus CL
    Clin Liver Dis; 2022 Nov; 26(4):705-726. PubMed ID: 36270725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies target the toxic consequences of cholestatic liver disease.
    Jansen PLM
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
    Wang C; Shi Y; Wang X; Ma H; Liu Q; Gao Y; Niu J
    Front Immunol; 2022; 13():940688. PubMed ID: 35880178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Mayo MJ
    Hepatology; 2022 Aug; 76(2):518-531. PubMed ID: 35152430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New name and new treatments for primary biliary cholangitits].
    Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
    Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases
    Nevens F; Trauner M; Manns MP
    J Hepatol; 2023 Feb; 78(2):430-441. PubMed ID: 36272496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.